2. Academic Validation
  3. Tanshinone IIA inhibits endometrial carcinoma growth through the MAPK/ERK/TRIB3 pathway

Tanshinone IIA inhibits endometrial carcinoma growth through the MAPK/ERK/TRIB3 pathway

  • Arch Biochem Biophys. 2023 Jun 5;109655. doi: 10.1016/j.abb.2023.109655.
Wenwen Zhang 1,  Meihua Liu 1,  Yurou Ji 2,  Dake Yu 3,  Chuanrui Ma 4,  Jianguo Zhao 5,  Pengpeng Qu 6
Affiliations

Affiliations

  • 1 Tianjin Central Hospital of Gynecology Obstetrics, No. 156 Nankai San Ma Road, Nankai District, Tianjin, 300100, China; Research Institute of Obstetrics and Gynecology, Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin, 300100, China.
  • 2 Clinical School of Obstetrics and Gynecology Center, Tianjin Medical University, No. 22 Meteorological Observatory Road, Heping District, Tianjin, 300070, China; Tianjin Medical University, No. 22 Meteorological Observatory Road, Heping District, Tianjin, 300070, China.
  • 3 Tianjin Central Hospital of Gynecology Obstetrics, No. 156 Nankai San Ma Road, Nankai District, Tianjin, 300100, China.
  • 4 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300192, China; Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome, Tianjin, 300192, China.
  • 5 Tianjin Central Hospital of Gynecology Obstetrics, No. 156 Nankai San Ma Road, Nankai District, Tianjin, 300100, China. Electronic address: [email protected].
  • 6 Tianjin Central Hospital of Gynecology Obstetrics, No. 156 Nankai San Ma Road, Nankai District, Tianjin, 300100, China; Research Institute of Obstetrics and Gynecology, Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin, 300100, China. Electronic address: [email protected].
PMID: 37285895 DOI: 10.1016/j.abb.2023.109655
Abstract

Endometrial carcinoma is the most common gynecological tumor in developed countries. Tanshinone IIA is a traditional herbal medicine which is to treat Cardiovascular Disease and has been shown to have various biological effects, such as anti-inflammatory, antioxidative and antitumor activities. However, there has been no study about the effect of tanshinone IIA on endometrial carcinoma. Thus, the aim of this study was to determine the antitumor activity of tanshinone IIA against endometrial carcinoma and investigate the associated molecular mechanism. We demonstrated that tanshinone IIA induced cell Apoptosis and inhibited migration. We further demonstrated that tanshinone IIA activated the intrinsic (mitochondrial) apoptotic pathway. Mechanistically, tanshinone IIA induced Apoptosis by upregulating TRIB3 expression and inhibiting the MAPK/ERK signaling pathway. In addition, knockdown of TRIB3 with an shRNA lentivirus accelerated proliferation and attenuated inhibition mediated by tanshinone IIA. Finally, we further demonstrated that tanshinone IIA inhibited tumor growth by inducing TRIB3 expression in vivo. In conclusion, these findings suggest that tanshinone IIA has a significant antitumor effect by inducing Apoptosis and may be used as a drug for the treatment of endometrial carcinoma.

Keywords

Cell apoptosis; Endometrial carcinoma; Tanshinone IIA.

Figures
Products